| A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Cancer Research 82 (12_Supplement), 5313-5313, 2022 | 1 | 2022 |
| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 408 | 2019 |
| BCL-2 proteins degraders for cancer treatment G Zheng, D Zhou, X Zhang, S Khan, HE Yonghan, P Zhang | 1 | 2019 |
| BCL-2 Proteins Degraders for Cancer Treatment G Zheng, D Zhou, X Zhang, S Khan, Y He, P Zhang US Patent App. 16/962,816, 2021 | | 2021 |
| BCL-X S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... | | 2022 |
| BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Journal of Hematology & Oncology 15 (1), 23, 2022 | 30 | 2022 |
| Centchroman altered the expressions of tumor‐related genes through active chromatin modifications in mammary cancer S Khan, S Shukla, S Sinha, SM Meeran Molecular Carcinogenesis 55 (11), 1747-1760, 2016 | 9 | 2016 |
| Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1/PAK1/β-catenin signaling axis S Khan, S Shukla, M Farhan, S Sinha, AD Lakra, D Penta, A Kannan, ... Life Sciences 256, 117976, 2020 | 21 | 2020 |
| Centchroman suppresses breast cancer metastasis by reversing epithelial–mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling S Khan, S Shukla, S Sinha, AD Lakra, HK Bora, SM Meeran The International Journal of Biochemistry & Cell Biology 58, 1-16, 2015 | 60 | 2015 |
| Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice S Khan, P Kellish, N Connis, D Thummuri, J Wiegand, P Zhang, X Zhang, ... Cell Death Discovery 9 (1), 1, 2023 | 8 | 2023 |
| Cucurbitacin B alters the expression of tumor-related genes by epigenetic modifications in NSCLC and inhibits NNK-induced lung tumorigenesis S Shukla, S Khan, S Kumar, S Sinha, M Farhan, HK Bora, R Maurya, ... Cancer prevention research 8 (6), 552-562, 2015 | 56 | 2015 |
| Cucurbitacin B inhibits breast cancer metastasis and angiogenesis through VEGF-mediated suppression of FAK/MMP-9 signaling axis S Sinha, S Khan, S Shukla, AD Lakra, S Kumar, G Das, R Maurya, ... The international journal of biochemistry & cell biology 77, 41-56, 2016 | 65 | 2016 |
| Cucurbitacin B inhibits the stemness and metastatic abilities of NSCLC via downregulation of canonical Wnt/β-catenin signaling axis S Shukla, S Sinha, S Khan, S Kumar, K Singh, K Mitra, R Maurya, ... Scientific reports 6 (1), 21860, 2016 | 73 | 2016 |
| DDR-targeting small molecule inhibitor as a novel therapeutic for treating pancreatic ductal adenocarcinoma TP Do, S Khan, D Zhou, M Hart, S McHardy, M Rao Cancer Research 83 (7_Supplement), 5004-5004, 2023 | | 2023 |
| DEGRADER OF BCL-2 PROTEIN FOR CANCER TREATMENT G Zheng, D Zhou, X Zhang, S Khan, HE Yonghan, P Zhang | | 2021 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 76 | 2021 |
| Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition P Pal, D Thummuri, D Lv, X Liu, P Zhang, W Hu, SK Poddar, N Hua, ... Journal of medicinal chemistry 64 (19), 14230-14246, 2021 | 31 | 2021 |
| Discovery of BCL-XL degraders as potent and platelet-sparing anticancer agents X Zhang, D Thummuri, S Khan, X Liu, P Zhang, D Zhou, G Zheng ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 258, 2019 | | 2019 |
| Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity D Thummuri, X Liu, W Hu, P Zhang, S Khan, Y Yuan, D Zhou, G Zheng ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 65 RUE CAMILLE …, 2020 | | 2020 |
| Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity X Zhang, D Thummuri, X Liu, W Hu, P Zhang, S Khan, Y Yuan, D Zhou, ... European journal of medicinal chemistry 192, 112186, 2020 | 73 | 2020 |
Peiyi ZhangChemist, University of Florida在 cop.ufl.edu 的电子邮件经过验证
